secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028484
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure reports $308.5M net loss in FY2023; cash $617.9M; pipeline programs advancing
--------------------------------------------------------------------------------

- Net loss $308.5M ($6.47 per share) vs $126.8M ($2.71) in FY2022; revenue $15.8M vs $106.5M.
- Cash and investments $617.9M as of Dec 31, 2023; expects to fund operations into Q2 2027.
- Strategic reorganization expected to deliver $180M in cost savings over three years.
- FDA clearance received for IND applications for AMT-260 (mTLE) and AMT-191 (Fabry); enrollment in Phase I/II trials expected H1 2024.
- Regulatory interactions for AMT-130 (Huntington's) approval pathway expected in 2024; interim data update in mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/0001104659-24-028484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/tm246858d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer